

Year	Date	Presenter	Title	Journal	Year	Vol	Page
2018	12/4	一瀬	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.	Am J Hematol.	2018	93	1301-1310
		波多	Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia	Nature medicine	2018	24	1859-1866
	12/11		ASH報告会 (安東・田口・藤岡)				
	12/18		ASH報告会 (宮崎)				
		古本	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia	J Clin Oncol.	2018	26	2684-2692.
	12/25	田口	Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations	Nature	2018	559	350-355
		安東	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.	Cancer Cell.	2018	34	225-241
2019	1/8	田口	学会予行				
	1/15	藤岡	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.	Bone Marrow Transplant.	2018		
		長井	Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.	Nat Med.	2019	25	82-88
	1/22	クリクラ生	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial	Lancet	2018		
		坂本	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.	J Clin Oncol.	2018		
	1/29	北之園	Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.	Leukemia.	2019	33	52-63
		澤山	Allogeneic BK Virus-Specific T Cells for PML	N Engl J Med	2019	379	1443-1451
	2/5	榊	Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.	Blood.	2018	132	2629-2638
	2/12	藤岡	移植学会予行				
	2/19	クリクラ生	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma	N Engl J Med	2018	379	1711-1721
		坂本	移植学会予行				
	2/26	古本	Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.	Haematologica.	2019	104	113-119
		今泉	JCOG班会議の報告				
	3/5	榊	血液内科学会予行				
	3/12	一瀬	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.	Blood.	2019	133	147-155
		宮崎	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.	Cell Stem cell.	2018	23	700-713
	3/19	渡辺	Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.	Leuk Lymphoma.	2019		
		佐藤	Neural cell adhesion molecule 1 (NCAM1; CD56) promotes leukemogenesis and confers drug resistance in AML.	Blood.	2019		
	3/26	坂本	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy	Leukemia	2019		
		波多	Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line	Blood.	2019	133	633-643